Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics announced new late-breaking data from its Phase 2 and Phase 3 trials showing that lorundrostat, a selective aldosterone synthase inhibitor, modulates heart failure risk biomarkers in patients with uncontrolled hypertension. The data will be presented at the Endocrine Society's annual meeting, highlighting lorundrostat's effic…